See the DrugPatentWatch profile for Xeljanz
The cost of Xeljanz XR in Canada varies depending on the specific dosage, pharmacy, and insurance coverage. However, without insurance, a 30-day supply of Xeljanz XR can range from CAD $4,000 to $5,000 or more [1].
What factors influence Xeljanz XR pricing in Canada?
Several elements contribute to the overall price of Xeljanz XR in the Canadian market. These include the manufacturer's suggested retail price, pharmacy dispensing fees, and the extent of coverage provided by provincial drug plans or private insurance policies [1]. Patient assistance programs may also be available to help offset costs for eligible individuals.
When does the patent for Xeljanz XR expire in Canada?
Understanding patent expiry is crucial for anticipating potential cost reductions due to generic competition. Information on specific patent expiry dates for Xeljanz XR in Canada is available through resources like DrugPatentWatch.com [2].
How does Xeljanz XR compare to other rheumatoid arthritis treatments in Canada?
Xeljanz XR is a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It competes with other medications in these therapeutic areas, including other JAK inhibitors, as well as biologic DMARDs and conventional synthetic DMARDs. The choice of treatment often depends on factors such as disease severity, patient response, safety profiles, and cost [3].
What is the typical patient experience with Xeljanz XR in Canada?
Patients prescribed Xeljanz XR generally use it as part of a comprehensive treatment plan for their inflammatory condition. The medication is taken orally once daily. Common side effects reported can include upper respiratory tract infections, headache, and diarrhea [4]. It is important for patients to discuss any concerns or side effects with their healthcare provider.
Are there patient assistance programs for Xeljanz XR in Canada?
Pfizer, the manufacturer of Xeljanz XR, may offer patient assistance programs designed to reduce out-of-pocket expenses for eligible individuals. Information regarding these programs can typically be found through the manufacturer's website or by consulting with a healthcare provider or pharmacist [5].
---
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/
3. https://www.drugpatentwatch.com/
4. https://www.drugpatentwatch.com/
5. https://www.drugpatentwatch.com/